

Efficacy of Combination of Meropenem with Gentamicin, and Amikacin against Resistant *E. coli* Isolated from Patients with UTIs: *in vitro* Study[#]

Maysaa A. Abdul Khaleq*¹, Abdulkareem H. Abd** and Maysaa A. Dhahi***

* Department of pharmacotherapeutics, College of Pharmacy, Al- Mustansiriyh University, Baghdad, Iraq.

** Department of pharmacology, College of Medicin, Al- Nahrain University, Baghdad, Iraq.

*** Department of Microbiology, College of Medicin, Al-Nahrain University, Baghdad, Iraq.

Abstract

Seventy five *E. coli* isolates were collected from urine of patients with urinary tract infections in AL-Kadhimia and AL-Yarmook teaching hospitals in Baghdad for a period between 22/11/2009 to 15/3/2010, from these samples twenty five isolates were selected according to their pattern of the highest resistance as these showing multi-drug resistances and tested to specify their minimum inhibitory concentration for (meropenem, gentamicin and amikacin), meropenem was found having the lowest MIC comparing with others. This study also includes *in vitro* effects of various combinations of three types of antimicrobials (meropenem, gentamicin and amikacin) against twenty five *E. coli* isolates. Among combinations the combination of meropenem with the other types of antimicrobials showed high synergistic effect when 1/4+1/4 MIC for each antimicrobial were used. While combinations of amikacin with gentamicin in some isolates showed additive effect when 1/2+1/2 MIC for each antimicrobial were used. The plasmid profile for the twenty five *E. coli* isolates were studied using Pure Yeild™ plasmid Miniprep system- Cat.# A1220 – Promega- USA. In order to determine the presence of plasmid for antimicrobials resistance.

الخلاصة

جمعت خمسة وسبعون عزلة من الاشيرويشيا القولونية من ادرار مرضى المجاري البولية الذين راجعوا مستشفى الكاظمية واليرموك التعليمي في بغداد للفترة من ٢٠٠٩/١١/٢٢ الى ٢٠١٠/٣/١٥ ومنهم تم اختيار خمسة وعشرون عزلة اعتماداً على ما أبدته من مقاومة عالية و متعددة للمضادات الجرثومية ثم حددت التراكيز المثبطة الدنيا (MIC) للمضادات (الميرونيم، الجنتاميسين والاميكاسين) وقد أظهرت النتائج بان مضاد الميرونيم هو الأكثر فاعلية و ذلك بتثبطه نمو البكتريا بأقل تركيز مقارنة بالمضادات الأخرى. تضمنت هذه الدراسة استقصاء تأثير اتحاد المضادات الحيوية ضد خمسة وعشرون عزلة من *E. coli* (*in vitro*) وقد أظهرت النتائج أن اتحاد الميرونيم مع بقية المضادات الحيوية (الجنتاميسين والاميكاسين) يشير الى تأثير تازري عالي عند استعمال ربع التركيز المثبط الأدنى (MIC) لكل مضاد حيوي. بينما اتحاد الاميكاسين مع الجنتاميسين في بعض العزلات يشير الى تأثير اضافي فقط عند استعمال نصف التركيز المثبط الأدنى (MIC) لكل مضاد حيوي. شملت الدراسة أيضاً دراسة النمط البلازميدي لخمسة وعشرون عزلة من بكتريا *E. coli* باستخدام عدة لعزل البلازميد بواسطة نظام Miniprep وقد أظهرت النتائج بأن العزلات (٣٢،٣٧،٥٧،٦) حاملة لبلازميد لمقاومة المضادات الحيوية.

Introduction

Urinary tract infections (UTIs) are one of the most common bacterial infections in humans both in the community and hospital setting⁽¹⁾. *Escherichia coli* have been documented to be the most important pathogen associated with symptomatic urinary tract infections⁽²⁾. plasmid DNA molecule is separate from, and can replicate independently of, the chromosomal DNA⁽³⁾. In this study we use combination of meropenem (which is a

broad spectrum antimicrobial agent with more activity against gram-negative bacilli and less activity against gram-positive cocci than is imipenem)⁽⁴⁾, with aminoglycosides which are polar compound with more activity against aerobic gram-negative bacilli and little activity against an aerobic bacteria and use with other antimicrobial agent against gram positive bacteria⁽⁵⁾.

[#] Based on oral presentation in the eighth scientific conference of the College of Pharmacy /University of Baghdad held in 23-24 February 2011.

¹ Corresponding author E- mail : maysaa_ali82a@yahoo.com

Received : 12/3/2011

Accepted : 10/5/2011

Material and Methods

The *E. coli* identification depended on morphological, biochemical testes in addition to API 20E system. Susceptibility of isolates to seventeenth antimicrobials was tested using disk diffusion assay according to modified Kirby–Bauer method⁽⁶⁾. Meropenem, nitrofurantoin, amikacin and imipenem were to be the most effective antimicrobials, while the other antimicrobials were less effective. Minimum inhibitory concentration (MIC) was determined using tubes dilution method⁽⁷⁾. The combination of antimicrobials whether it's synergistic, additives, antagonistic, or indifference depending on the fractional inhibitory concentration (FIC) was determined as follow: (≤ 0.5) synergism, ($0.5 < \text{FIC} < 1$) additive, ($1 < \text{FIC} < 4$) indifference, (≥ 4) antagonism, and calculated using the following equation⁽⁸⁾.

$$\text{FIC} = \frac{\text{MIC for antibiotic in combination}}{\text{MIC for antibiotic alone}}$$

Plasmid DNA isolated using Pure Yield™ plasmid Miniprep system, according to the manufacture manual. Then the extracted plasmid DNA was loaded in 0.8% agarose gel stained with ethidium bromide and electrophoresis for 60 minutes at 2V/Cm using 1X TBE buffer. Then agarose gel was visualized using UV-transluminator.

Result and Discussion

Colonies of *E. coli* had marked as a flat smooth and pink in color as a result of lactose fermentation in the media on MacConky agar, while on blood agar it gave small pink convex colonies surrounded by zone of β - haemolysis. In Microscopic Examination it showed as small single bacilli non spore forming with red color (gram –negative bacteria), it occurred separately and singly, but often they are accumulated in groups. The result of biochemical tests for most of *E. coli* showed its ability to catalase production and lactose fermentation while it gave a negative result in Oxidase, Urease and Simmon Citrate tests. Further identification of the isolates was done by using Api 20E system, as in Figure (1).



E. coli (4)

Figure 1: Identification of *E. coli* by Api20E system

Antimicrobial Sensitivity Test

1-Qualitative Method (Disc Diffusion Test)

In this study we found that antimicrobials sensitivity among *E. coli* isolates varied according to the nature of antimicrobials. The percentage of resistant isolates to each antimicrobial is shown in Figure (2). Standard disc diffusion assay was used to detect the sensitivity of pathogenic bacteria and results obtained were compared with those of Clinical and laboratory standard institute⁽⁹⁾. The results of the current study (Figure 2) revealed that most of *E. coli* isolates resist the β - lactam antimicrobials (like ampicillin and amoxicillin)⁽¹⁰⁾. noted the high

resistance rates of gram positive and gram negative species to penicillins and some of cephalosporins. Increasing of bacterial resistance rates to this group of antimicrobials may be a result of either production of β -lactamase enzyme that had the ability to destroy the β - lactam ring in these antimicrobials^(11, 12). Also it may be due to minimizing the interaction of antimicrobials with target site (Penicillin Binding Proteins)⁽¹³⁾. Augmentin (amoxicillin + clavulanic acid) had more activity than other penicillin due to its presence of clavulanic acid, which inhibit β - lactamase enzyme, and increase the spectrum of amoxicillin against gram- positive

and gram- negative bacteria⁽¹⁴⁾. Many research illustrated the higher activity of imipenem and meropenem (related to carbapenems group) against gram- positive and gram- negative bacteria⁽¹⁵⁾. Regarding aminoglycoside group, amikacin was more active than gentamicin on the current *E. coli* isolates, many researches showed that the increasing resistance against aminoglycoside group was due to production of the modified enzymes and losing outer membrane pores, which are responsible of permeability of surface cell layer to antimicrobials⁽¹⁶⁾. The current results (Figure 2) was in agreement with that of Shevelev *et al.* (2002)⁽¹⁷⁾ who found in a study that the resistance percentage of the isolates to amikacin was (0%) , while the resistant rate to gentamicin was (48.6%). The results also was in agreement with Bashir *et al.* (2008)⁽¹⁸⁾ who found in a study in Pakistan that the resistance percentage of the isolates to gentamicin was (49%) . Resistant to tobramycin was (40.7%) and this result was near that found by Pape *et al.* (2004)⁽¹⁹⁾ who found that the resistant percentage of *E. coli* to tobramycin was (30%). Many studies were illustrated the activity of naldixic acid, and most of quinolones antimicrobials against wide range

of bacteria that were in a good agreement with the currently result. For example the resistant rate to ciprofloxacin was (40.7%) this result was comparable to the result of Shamm *et al.* (2001)⁽²⁰⁾ found in a study that the resistant percentage of *E. coli* to ciprofloxacin was (39%). Resistance to piperacillin was (85.5%), this result was in agreement with that of Bujdakova *et al.* (1998)⁽²¹⁾ who found that (86%) of *E. coli* isolates resistant to piperacillin , and this may be due to the ability of *E. coli* to develop resistance to these antimicrobials through the production of β -lactamase enzyme which break the β -lactam ring of piperacillin. Resistance to nitrofurantoin was (2.6%), this result was in agreement with Akyar (2008)⁽²²⁾ who found that the resistant rate of *E. coli* against nitrofurantoin was (3%). Resistance to trimethoprim/ sulfamethoxazole (SXT) was (43.4%), this result may be attributed to the wide use of (SXT) as empirical therapy for urinary tract infection, however this result was in agreement with Gupta; Hooton and Stamm (2001)⁽²³⁾ who found that the resistance to (SXT) among *E. coli* isolates from patient with UTIs has increased, with a prevalence of resistance which is reported 30 to 50 percent .




Figure 2: Percentage of resistant *E. coli* isolates to antimicrobial

ToB: Tobramycin; CN: Gentamicin; Sxt: Triomethoprim and sulfamethoxazole; Cip: Ciprofloxacin; Na: Naldixic acid; Ctx: Cefotaxime; Ipm: Imipenim; Am: Ampicillin; CL: Cephalexin; CRO: Ceftriaxone; AMC: Amoxicillin and Clavulonic acid; F: Nitrofurantoin; AZM: Azithromycin; PRL: Piperacillin; MPM: Meropenem; AX: Amoxicillin AK: Amikacin

2- Quantitative Method (Minimum Inhibitory Concentration) (MIC)

Table 1 showed that MIC of meropenem ranged from (0.003-12.5 μ g/ml) this result was in agreement with Marie *et al.*⁽²⁴⁾ who found in his study that *E. coli* was moderately susceptible to meropenem at MIC (8 μ g/ml)

The results of this study also showed that the MIC of gentamicin ranged from (12.5 to 480 μ g/ml), this result was in agreement with Jakobsem *et al.*⁽²⁵⁾ who found in his study that the MIC of gentamicin distributed from (8-512 μ g/ml). On the other hand MIC of

amikacin ranged from (0.3-2.5µg/ml), this result was in agreement with Shrivastava and Chaudhary⁽²⁶⁾ whose found that the MIC of amikacin in *E. coli* was (2µg/ml).while Celine

et al.⁽²⁷⁾ who found in his study that the MIC of amikacin in *E. coli* ranged from (1 to16 µg/ml).

Table 1: MIC value for three antimicrobials (µg/ml) tested against *E. coli* isolates

E. coli isolates	Meropenem µg/ml		Gentamicin µg/ml		Amikacin µg/ml	
	MIC	MBC	MIC	MBC	MIC	MBC
A1	0.12	0.125	300	300	2.5	5
A2	1.25	12.5	200	300	1.25	2.5
A3	0.12	1.25	300	300	1.25	2.5
A4	1.25	1.25	300	480	0.6	1.25
A6	0.12	1.25	480	480	0.3	0.6
A7	1.25	1.25	300	300	2.5	5
A10	12.5	12.5	480	480	0.6	1.25
A11	0.003	0.003	12.5	12.5	1.25	2.5
A13	0.12	0.12	300	300	2.5	5
A24	0.12	1.2	300	300	1.25	2.5
A28	0.03	0.03	200	200	1.25	2.5
A32	12.5	12.5	480	480	0.6	1.25
A35	1.25	1.25	200	300	0.6	1.25
A37	0.12	1.25	480	480	0.3	0.6
A41	12.5	12.5	100	200	1.25	2.5
A42	12.5	12.5	100	200	1.25	2.5
A43	1.25	1.25	200	300	0.6	1.25
A44	0.06	0.06	200	300	2.5	5
A45	1.25	12.5	200	300	1.25	2.5
A47	0.12	1.25	480	480	0.3	0.6
A51	12.5	12.5	100	200	1.25	2.5
A55	0.06	0.03	200	300	2.5	5
A57	0.12	1.25	480	480	0.3	0.6
A58	0.12	0.12	300	300	2.5	5
A67	0.12	0.125	300	300	2.5	5
LSD value	4.945 *	5.418 *	137.95 *	118.38 *	0.830 *	1.651 *

* (P<0.05), LSD: Least significant difference

3- Antimicrobials Combination

The result in Table2 shows that the synergistic effect noticed from combination of meropenem with gentamicin on isolate No. (1, 2, 3, 4, 6, 7, 10, 13, 24, 28, 35, 37, 41, 42, 43, 44, 45, 47, 51, 55, 57, 58, 67), this result similar to that shown by Richared *et al.*⁽²⁸⁾ found that aminoglycoside synergized with β-lactams antimicrobials against *E. coli* isolates, because of the latter action on cell wall synthesis, which enhance diffusion of the aminoglycoside into the bacterium. While isolate No.(32) show the additive effect with combination of meropenem with gentamicin, and that may be due to their resistance to gentamicin (MIC 480) and to meropenem

(MIC 12.5). table3 shows Another synergistic effect resulted from combination of meropenem with amikacin when its effect tested on isolate No. (1, 2, 3, 4, 7, 10, 13, 24, 28, 37, 41,42,43, 44,45,47, 51, 55, 57, 58, 67) this result was in agreement with and Piroaska *et al.*⁽²⁹⁾ whose found that there is synergistic effect result from combination of meropenem with amikacin against *E. coli* isolates . While isolates No. (6, 32, 35) showed no effect toward combination of meropenem with amikacin.On the other hand combination of amikacin with gentamicin (table 4 showed additive effect when tested on isolates No. (1, 2) but other isolates show no effect.

Table2: Results of combination of meropenem with gentamicin (1/4+1/4MIC)

<i>E. Coli</i> isolates	MIC of meropenem before combination (ug/ml)	MIC of meropenem after combination (ug/ml)	MIC of gentamicin before combination (ug/ml)	MIC of gentamicin after combination (ug/ml)	FIC	Result
A1	0.12	0.03	300	75	0.5	Syn
A2	1.25	0.31	200	50	0.5	Syn
A3	0.12	0.03	300	75	0.5	Syn
A4	1.25	0.31	300	75	0.5	Syn
A6	0.12	0.03	480	120	0.5	Syn
A7	1.25	0.31	300	75	0.5	Syn
A10	12.5	3.125	480	120	0.5	Syn
A13	0.12	0.03	300	75	0.5	Syn
A28	0.03	0.007	200	50	0.5	Syn
A24	0.12	0.03	300	75	0.5	Syn
A35	1.25	0.31	200	50	0.5	Syn
A37	0.12	0.03	480	120	0.5	Syn
A41	12.5	3.12	100	25	0.5	Syn
A42	12.5	3.12	100	25	0.5	Syn
A43	1.25	0.31	200	50	0.5	Syn
A44	0.06	0.015	200	50	0.5	Syn
A45	1.25	0.31	200	50	0.5	Syn
A47	0.12	0.03	480	120	0.5	Syn
A51	12.5	3.12	100	25	0.5	Syn
A55	0.06	0.01	200	50	0.5	Syn
A57	0.12	0.03	480	120	0.5	Syn
A58	0.12	0.03	300	75	0.5	Syn
A67	0.12	0.03	300	75	0.5	Syn
LSD value	5.030 *	4.234 *	213.56 *	122.23 *	--	--

* (P<0.05); LSD: Least significant difference; Syn: Synergism; FIC: Fractional Inhibitory Concentration

Table 3: Results of combination of meropenem with amikacin (1/4+1/4 MIC):

<i>E. Coli</i> isolates	MIC of meropenem before combination (ug/ml)	MIC of meropenem after combination (ug/ml)	MIC of amikacin before combination (ug/ml)	MIC of amikacin after combination (ug/ml)	FIC	Result
A1	0.12	0.03	2.5	0.62	0.5	Syn
A2	1.25	0.31	1.25	0.31	0.5	Syn
A3	0.12	0.03	1.25	0.31	0.5	Syn
A4	1.25	0.31	0.6	0.15	0.5	Syn
A7	1.25	0.31	2.5	0.62	0.5	Syn
A10	12.5	3.12	0.6	0.15	0.5	Syn
A13	0.12	0.03	2.5	0.62	0.5	Syn
A24	0.12	0.03	1.25	0.31	0.5	Syn
A28	0.03	0.007	1.25	0.31	0.5	Syn
A37	0.12	0.03	0.3	0.07	0.5	Syn
A41	12.5	3.12	1.25	0.31	0.5	Syn
A42	12.5	3.12	1.25	0.31	0.5	Syn
A43	1.25	0.31	0.6	0.15	0.5	Syn
A44	0.06	0.01	2.5	0.62	0.5	Syn
A45	1.25	0.31	1.25	0.31	0.5	Syn
A47	0.12	0.03	0.3	0.07	0.5	Syn
A51	12.5	3.12	1.25	0.31	0.5	Syn
A55	0.06	0.01	2.5	0.62	0.5	Syn
A57	0.12	0.03	0.3	0.07	0.5	Syn
A58	0.12	0.03	2.5	0.62	0.5	Syn
A67	0.12	0.03	2.5	0.62	0.5	Syn
LSD value	5.030 *	4.234 *	213.56 *	122.23 *	--	--

* (P<0.05); LSD: Least significant difference; Syn: Synergism; FIC: Fractional Inhibitory Concentrations

Table 4: Antimicrobials combination (1/2+1/2 MIC for each antimicrobials)

<i>E. coli</i> isolates	Antimicrobials combination	MIC of first antimicrobial alone (µg/ml)	MIC of first antimicrobial in combination (µg/ml)	MIC of second antimicrobial alone (µg/ml)	MIC of second antimicrobial in combination (µg/ml)	FIC	Results
A32	MPM+CN	12.5	6.25	480	240	1	Add
A1	AK+CN	2.5	1.25	300	150	1	Add
A2	AK+CN	1.25	0.625	200	100	1	Add

Add: Addition; FIC: Fractional Inhibitory Concentration MPM: meropenem; CN: gentamicin; AK: amikacin.

Extraction of Plasmid DNA

The result of Figures (3 and 4) indicate that each of the isolates (A6, A37) containing two bands of plasmid DNA with approximate molecular weight (2000 and 1900) bp comparing with molecular weight marker. Also, isolates No. (A32, A57) containing one plasmid DNA with approximate molecular weight (2000) bp when comparing with molecular weight marker. There are many studies referred to the isolation of antimicrobial resistance plasmid from *E. coli*. Joseph *et al.* (2001)⁽³⁰⁾ found in their study that *E. coli* isolates contain plasmid coding for resistance of aminoglycoside antimicrobials, including gentamicin and tobramycin. Also, March Galimand *et al.* (2003)⁽³¹⁾ found in their study that *E. coli* isolated from patient

suffering from urinary tract infection contain plasmid coding high level of resistance to aminoglycoside. Piddock (1999)⁽³²⁾ found in his study that *E. coli* contain plasmid coding for resistance of fluoroquinolone. Sisson *et al.* (2002)⁽³³⁾ found in their study that resistance to nitrofurantoin may be chromosomal or plasmid mediated. Minch Chau Phuc Nguyen *et al.* (2002)⁽³⁴⁾ found in their study that the plasmid gene that confers resistance to azithromycin had recently emerged in non multidrug resistant *E. coli*; Philippon; Arlet and Jacoby (2002)⁽³⁵⁾ found in their study that *E. coli* contains plasmid coding for resistance of ampicillin. In the other hand, other *E. coli* isolates that show no plasmid may be due to carrying plasmids with low copy number.




Figure 3: plasmid profile of *E. coli* strains Lane (A6, A37, A57, A32): Plasmid DNA extracted from *E. coli* strains; M.W: Molecular weight marker of lambda DNA digested with EcoRI+HindIII. Electrophoresis was carried in 0.8% agarose gel at (2V/Cm) for 30 min.




Figure 4: plasmid profile of *E. coli* strains isolated from UTIs patients Lane (A6, A37, A57, A32): Plasmid DNA extracted from *E. coli* strains; M.W: Molecular weight marker of lambda DNA digested with EcoRI+HindIII . Electrophoresis was carried in 0.8% agarose gel at (2V/Cm) for 60 min.

Reference

1. David, S.; and Howes ,MD. Urinary tract infection in female;2009;27.
2. Musa-Aisien, AS.; Ibadin ,OM.; and Ukoh ,G. Prevalence and antimicrobial sensitivity pattern in urinary tract infection in febrile under-55 at a childrens' emergency unit in Nigeria. Annual of tropical pediatric; 2003;23:39-45.
3. Lipps G. Plasmids: Current Research and Future Trends; Caister Academic Press;2008.
4. Henry, F.; and Chambers, MD. Basic and clinical pharmacology .10th ed. In: Bertram G. and Katzung M.D. Lang medical book /Mc Graw Hill;2007; PP. 726 -770.
5. Falagas, ME.; Grammatikos, AP.; and Michalopoulos, A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert. Rev. Anti. Infect. Ther;2008; 6(5): 593-600.
6. Vandepitte, J. ;and Verhaegen, J.; Engbaek, K.; Rohner, P.; Piot ,P.; Heuck ,C.C. Basic laboratory procedures in clinical bacteriology. 2nd ed. World health organization;2003; PP.30 :109-115.
7. Michael, J.; Leboffe and Bruton, E.; Pierce. A photographic atlas for the 3ed ed. Microbiology laboratory /Douglas, N. Morton, Inc.2005.
8. American society for microbiology. Instructions to Authors.S.I: Antimicrob. Agents chemother;2002; 46:i-xix.
9. Clinical and laboratory standard institute (CLSI) .Performance standard for antimicrobial susceptibility testing. 17th informational supplement; Document M100-S17; Clinical and laboratory standards institute;2007;Vol.27.No.1.
10. Akther, J.; Qutub, M.; and Qadri, S. Antimicrobial susceptibility testing and patterns of resistance at tertiary care center in Saudi . Med. J.; 2001;22(7):569- 576.
11. Gupta, K.; Scholes, D.; and Stamm, W. Increasing prevalenceof antimicrobial resistance among pathogens causing acute uncomplicated cystitis in women. JAMJ;1999; 281:736-738.
12. Murray, P.R.; Baron, E.J.; Pefaller, M.A.; Tenover, F.C.; and Tenover, R.H. Manual of clinical microbiology. 7th ed. ASM press. USA.;1999.
13. Clark,W.G.; Brater, D.C.; and Johnson, A.R. Medic pharmacology Goth's in to chemotherapy mechanisms of antimicrobial. International press;1992.

14. Normann, P.; Ronse, E.; Nass, T.; Dupont, C.; and Labia, R. Characterization of a novel extended-spectrum β -lactamase from *Pseudomonas aeruginosa*. *Antimicrob. Chemother.*; 1993; 37(5): 962-969.
15. Gales, AC.; Sader, HS.; And Jones, RN. Urinary tract infection trends in latin American hospitals: report from the sentry antimicrobial surveillance program (1997-2000). *Diagnostic microbiology and infect Dis.*; 2002; 44: 289-299.
16. Vatopoulos, A.; Tsakris, A.; Tzouveleki, L.; Legakis, N.; Pitt, T.; and Komninou, Z. Diversity of aminoglycosides resistance in *Enterobacter Cloacaein Greece*. *J. Clin. Microbiol. Infect. Dis.*; 1992 ; 11(2): 131-138.
17. Shevelev, A.; Reshedko, G.; Edelstein, I.; Kozlova, L.; Korovina, N.; Zorkin, S.; Katosova, L.; Papajan, A.; Marusina, N.; Alumetova, L.; Vjalkova, A.; Agapova, E.; and Fokina, B. Mechanisms of resistance to aminoglycosides (amg) *E. coli* isolates from children with community-acquired urinary tract infections, 4th European congress of chemotherapy and infection. Paris; France; 2002.
18. Bashir, MF.; Qazi, JI.; Ahmad, N.; and Riaz, S. Diversity of urinary tract pathogens and drug resistant isolates of *Escherichia coli* in different age and gender groups of Pakistanis. *Tropical journal of pharmaceutical research*; 2008; 7(3): 1025-1031.
19. Pape, L.; Gunzer, F.; Ziesing, S.; Pape, A.; Offner, G.; and Ehrich, JH. Bacterial pathogens, resistance patterns and treatment options in community acquired pediatric urinary tract infection. *Klin padiatr*; 2004; 216(2): 83-86.
20. Sahm, D.F., C.; Thornsberry, C.; Mayfield, D.C.; Jones, M.E.; and Karlowsky, J.A. Multi-drug resistant urinary tract isolates of *Escherichia coli*: Prevalence and patient demographics in united states in 2000. *Antimicrob. Agents; Chemother*; 2001; 45: 1402-1406.
21. Bujdakova, H.; Lausova, A.; Jankovicova, S.; Prodingler, W.M.; Kallova, J.; Milosovic, P.; and Kettner, M. Study of β -lactam resistance in ceftazidime resistant clinical isolates of enterobacteriaceae. *J. Antimicrob. Agents*; 1998; 10: 136-414.
22. Akyar, I. Antibiotic resistance rates of extended spectrum beta lactamas producing *Escherichia coli* and *Klebsiella spp.* Strains isolated from urinary tract infection in a private hospital. *Microbiol. Bull. National center of biotechnology information, U.S. National library of medicine*; 2008.
23. Gupta, K.; Hooton, TM.; and Stamm, WE. Increasing antimicrobial resistance and the management of un complicated community acquired urinary tract infections. *Ann. Internal medicine*; 2001; 135: 41-50.
24. Mari- Frederique; Laurent poirel; Claire poyart; Helene reglier- poupet; and Patrice nordmann. Ertapenem resistance of *Escherichia coli*; 2007; Vol. 13. Number 2.
25. Jakobsen, L.; Sandvang, D.; Jensen, V.F.; Seyfarth, A.M.; Frimodt- Moller, N.; and Hammerum, A.M. Gentamicin susceptibility in *Escherichia coli* related to the genetic back ground :problems with break points. *Clinical microbiology and infection. Blak well publishing*; 2007; Vol. 13. Number 8; PP. 830-832.
26. Shrivastava, S.M.; and Chaudhary, M. Comparative studies on susceptibility and minimum inhibitory concentration of potentox, a fixed dose combination of cefepime and amikacin in *Proteus vulgaris*, *Escherichia coli* and *Bacillus subtilis*. *Journal of medical science*; 2009; Vol. 9; PP. 245-248.
27. Celine Vidaillac; Steve, N. Leonard; Helie, S. Sader; Ronald, N. Jones; and Michael, J. Rybak. "In vitro activity of ceftaroline alone and in combination against clinical isolates of resistance gram-negative pathogens, including β -lactamase-producing Enterobacteriaceae and *Pseudomonas aeruginosa*". *Antimicrobial agents and chemo.therapy*; 2009; Vol. 53. No. 6 PP. 2360-2366.
28. Richard, A. Harvey; Pamela, C. Champe. Protein synthesis inhibitors; In: Richard, D. Howland ; Mary, J. Mycek. *Lippincotts illustrated reviews. 3ed ed. Lippincott Williams and Wikins*; 2006; PP. 363-393.
29. Piroska Anderlike; Ferenc Rozgonyia; and Kajroly Nagya. The effect of amikacin and imipenem alone and in combination against an extended-spectrum β -lactamase producing *Klebsiella pneumonia* and *E. coli* strain; 2007; Vol. 58. Issue 1. PP. 105-110.
30. Joseph, W. Chow; Vivek, kAk.; Ilyou; Susan, J. Kao; Joanne Petrin; Don, B. Clewell ; Stephen, A. Lerner; George, H. Miller; and Karen, J. Shaw. Aminoglycoside resistance genes aph (2)-Ib and aac-Im detected together in strains of both *Escherichia coli* and *Enterococcus faecium*. *Antimicrobial agents and chemotherapy*; 2001; Vol. 45. PP. 2691-2694.
31. Marc Galimand; Patrice Courvalin; and Thierry Lambert. Plasmid-mediated high-level

- resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation, antimicrobial agents and chemotherapy;2003;Vol. 47.PP.2565-2571.
32. Piddoch, L.J. Mechanisms of fluoroquinolone resistance. *Drugs*;1999;58 (suppl2)11-18.
33. Sisson, G.; Goodwin, A.; Raudonikiene, A.; Hushes, N.J.; Mukhopadhyay, A.K.; Berg, D.E.; and Hoffman, P.S. Structural and mechanistic studies of *Escherichia coli* nitroreductase with the antibiotic nitrofurazone. *Antimicrobial agents and chemotherapy*;2002; 46, 2116-212.
34. Minhchan Plac Ngugen; Paul Louis Woerther; Mathilde Bouvet; Antoine Andremon; Roland Leclercq; and Annie Canu. *Escherichia coli* as reservoir for macrolide resistance genes. *Emerging infectious disease*;2009;Vol. 15. No.10.
35. Philippon, A.; Arlet, B.; Jacoby, G.A. Plasmid-determined AmpC-type β -lactamases. *Antimicrobial agent chemotherapy*; 2002; 46:1-11.